CASE STUDY
Why Localize Pharmaceutical Manufacturing in China?
A strategic guide for biologics, chemical drugs, and generics — published in partnership with CR Gosun
China’s Volume-Based Procurement system now commands 70–80% of public hospital drug volume. Local manufacturing isn’t optional for companies that want to compete.
This case study, produced by PharmaSource in partnership with CR Gosun, lays out what pharmaceutical localization actually requires — regulatory pathways, IP considerations, fill-finish strategy, and real-world outcomes from two manufacturer partnerships spanning more than 15 years.
How local manufacturing eliminates 3–4 months of import delays and preserves shelf life that imported products routinely lose in transit
Why VBP participation is effectively impossible without local production — and what 50–96% price reductions mean for cost strategy
The regulatory pathway for localization: priority review eligibility, data reuse, and the key differences between chemical drugs and biologics
Fill-finish as a lower-risk entry point: what transfers to a local partner, what stays with the originator
Case study: how Basilea Pharmaceutica achieved a 75–80% supply chain compression and NMPA approval in under 12 months
30 years of sterile injectable expertise, including a 15-year manufacturing partnership with a global top-10 pharma company